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The Vma21p protein in yeast is an essential assembly chaperone for the vacuolar ATPase, the 
major proton pump of cellular membranes. In this issue, Ramachandran et al. (2009) report that 
mutations in the gene encoding the human homolog VMA21 cause the disease X-linked myopathy 
with excessive autophagy through an unexpected mechanism.Tight regulation of pH in intracellular 
compartments is critical for multiple 
cellular processes, including mem-
brane trafficking, coupled transport 
of molecules, and protein degradation 
(Forgac, 2007). Transport of hydro-
gen ions across cellular membranes is 
predominantly conducted by a proton 
pump, the vacuolar ATPase (V-ATPase). 
This rotary nanomachine comprises 13 
subunits that form an ATP-hydrolytic 
domain (V1) and a proton-transloca-
tor domain (V0). V-ATPases are also 
expressed in the plasma membranes 
of specialized cells and contribute to 
multiple functions, such as renal acidi-
fication, bone resorption, sperm matu-
ration, and control of cytoplasmic pH. 
Mutations in cell-specific isoforms of 
V-ATPase subunits cause tissue-spe-
cific diseases. For example, mutations 
of the a2 isoform (in the Golgi and early 
endosomes of endothelial cells) cause 
developmental delays and wrinkled 
skin (Kornak et al., 2008); mutations 
in a3 (in the osteoclast plasma mem-
brane) cause osteopetrosis (Frattini et 
al., 2000); mutations in a4 (in the plasma 
membrane of distal nephron and inner 
ear cells) cause renal tubular acidosis 
and deafness (Karet et al., 1999). In 
this issue, Ramachandran et al. (2009) 
now characterize a general defect in 
V-ATPase function caused by muta-
tions in an essential chaperone, VMA21, 
that result in muscle-specific disease 
in humans. The authors show that 
VMA21 deficiency decreases V-ATPase 
activity, resulting in an increase in int-
ralysosomal pH. This increase in pH 
impairs lysosomal action and blocks the autophagic degradation of proteins 
leading to accumulation of autophago-
somes and autophagic vacuoles.
Through linkage studies and candi-
date gene sequencing, Ramachandran 
et al. (2009) identified six single-nucle-
otide substitutions in the LOC203547 
gene in male patients from 14 fami-
lies with a rare disease called X-linked 
myopathy with excessive autophagy 
(XMEA). This childhood-onset disor-
der is characterized by the progres-
sive atrophy and vacuolation of skeletal 
muscle (Kalimo et al., 1988). Because 
all of the mutations resulted in down-
regulation of the LOC203547 transcript 
and its protein product in the muscle 
cells of XMEA patients, the defective 
genes were considered to be hypomor-
phic alleles. To confirm that the muta-
tions were pathogenic, the authors 
documented that the abnormalities in 
autophagy they observed in fibroblasts 
from XMEA patients could be corrected 
by stable transfection with a retrovirus 
expressing the normal gene. Although 
the LOC203547 gene product has only 
?20% identity with yeast Vma21p, 
the authors posit that the proteins are 
orthologs and accordingly designate 
the human version VMA21. In support of 
this notion, the human gene rescued the 
growth defects of yeast vma21 deletion 
mutants cultured under both normal 
and stress conditions.
Ramachandran and colleagues dem-
onstrate that the functions of human 
VMA21 are similar, but not identical, to 
those of yeast Vma21p. Both proteins 
are required to initiate assembly of the 
proton-translocator domain V0 of the CellV-ATPase in the endoplasmic reticulum 
(ER), but Vma21p interacts with sub-
unit c′ of V0, whereas VMA21 interacts 
with subunit c′′ (Figure 1A). Both pro-
teins chaperone the V0 domain in COPII 
vesicles during transport from the ER to 
the ER-Golgi intermediate compartment 
(ERGIC) and to the Golgi apparatus, 
where V-ATPase assembly is completed 
by addition of the V1 ATP-hydrolytic 
domain (Figure 1). However, in contrast 
to Vma21p, which is recycled back to the 
ER by COPI vesicles via a carboxy-ter-
minal dilysine signal, VMA21 lacks this 
signal and does not return to the ER.
Lysosomes are critical for the degra-
dation of excess or damaged proteins 
and organelles by autophagy. There are 
three types of autophagy: chaperone-
mediated autophagy, microautophagy, 
and macroautophagy (Mizushima et al., 
2008). Chaperone-mediated autophagy 
results in degradation of soluble proteins, 
whereas micro- and macroautophagy 
result in engulfment of large structures 
via selective and nonselective mecha-
nisms to produce autophagosomes. In 
chaperone-mediated autophagy, chap-
erone-bound proteins are targeted to 
lysosomes, to which they gain access 
through a membrane receptor called 
LAMP2A (lysosome-associated mem-
brane protein 2A). In microautophagy, 
cytosolic components are pocketed 
by lysosomes through invaginations of 
the organellar membrane. In macroau-
tophagy, double-membrane structures 
called phagophores surround the tar-
gets for degradation to form double-
membrane autophagosomes. Autopha-
gosomes then fuse with lysosomes to  137, April 17, 2009 ©2009 Elsevier Inc. 213
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(A) The chaperone VMA21 (red circle) binds to the 
c′′ subunit of the vacuolar-ATPase (V-ATPase; dark 
green) in the endoplasmic reticulum and initiates 
assembly of the proton-translocator domain (V0; 
pale green) (Ramachandran et al., 2009). VMA21 
chaperones V0 in COPII vesicles to the endoplas-
mic reticulum Golgi intermediate complex (ER-
GIC). VMA21 is not present in the Golgi apparatus, 
but it is here that V-ATPase assembly is complet-
ed by addition of the ATP-hydrolytic domain (V1; 
turquoise). Proton pumping by the V-ATPase is 
critical for regulating the pH of lysosomes. Fusion 
of lysosomes with autophagosomes generates 
autolysosomes that degrade target proteins and 
organelles.
(B) In the disease X-linked myopathy with exces-
sive autophagy (XMEA), deficiency of VMA21 
leads to failure of V0 assembly, reduced levels of 
V-ATPase, and a decrease in lysosomal pH that 
impairs lysosomal and autophagic digestion of 
cellular proteins and organelles. Decreased pro-
tein degradation in XMEA may lower intracellular 
levels of amino acids that modulate the mTOR 
signaling pathway, which, in turn, upregulates 
macroautophagy. This leads to excessive accu-
mulation of autophagosomes, autolysosomes, 
and autophagic vacuoles and a muscle-specific 
disease phenotype.generate autolysosomes, which, in turn, 
coalesce to form autophagic vacuoles 
(Figure 1A).
Given the functions of VMA21, it is not 
surprising that deficiency of this protein 
would cause marked loss of V-ATPase 
complexes in the organelles of muscle 
and of cultured fibroblasts and lympho-
blasts from XMEA patients (Figure 1B). 
As a consequence of V-ATPase defi-
ciency, the lysosomal pH is 0.5 units 
higher in fibroblasts from XMEA patients 
than in those from healthy individuals. 
The lysosomal pH is altered enough to 
decrease the autophagic degradation of 
long-lived proteins, but not the matura-
tion of three lysosomal enzymes. This 
led Ramachandran et al. to hypothesize 
that the higher lysosomal pH reduces 
enzymatic activities in the autophagic 
pathway selectively, thus resulting in the 
accumulation of autophagic vacuoles in XMEA. This concept is supported by 
reports that pharmacological inhibition 
of V-ATPase in cells impairs autophagy 
and increases the numbers of autolyso-
somes and autophagic vacuoles (Shacka 
et al., 2006). Nevertheless, direct evi-
dence of altered autolysosomal pH and 
of its effects on macroautophagic pro-
tein degradation in XMEA is still wanting. 
Although not noted by the authors, lack 
of lysosomal upregulation in response to 
the overabundance of autophagosomes 
may also contribute to the delayed deg-
radation of the contents of autophagic 
vacuoles.
Ramachandran et al. further postulate 
that the block in autophagy would result 
in upregulation of macroautophagy. In 
agreement with this notion, they did 
observe an increase in early components 
of the macroautophagic activation path-
way including beclin-1, beclin-1-hVps34 complexes, and LC3. They further pro-
pose that decreased recycling of excess 
and degraded proteins and the reduced 
liberation of amino acids enhances 
autophagy because a decrease in amino 
acids in the cytoplasm modulates the 
mTOR signaling pathway, which then 
upregulates macroautophagy (Figure 
1B). In support of this hypothesis, the 
authors noted prominent dephospho-
rylation of p70S6 kinase, a key compo-
nent of the mechanism by which mTOR 
upregulates macroautophagy. They 
also observed that partial inhibition of 
lysosomal hydrolases by leupeptin in 
control fibroblasts and lymphoblasts 
resulted in mTOR-mediated upregula-
tion of microautophagy, reflected by 
proliferation of autolysosomes and 
autophagic vacuoles. If the authors’ 
notion that macroautophagy in XMEA 
is enhanced by activation of mTOR is 
correct, then blocking this pathway to 
reduce autophagy may prove beneficial 
to patients. This potentially useful thera-
peutic strategy can be assessed in cell 
culture models using pharmacological 
blockade or genetic interventions such 
as RNA interference.
An issue that could not be addressed 
experimentally in the Ramachandran 
et al. study is why a general defect in 
V-ATPase, a housekeeping protein com-
plex, should cause a skeletal muscle-
specific phenotype. The authors specu-
late that the preferential involvement of 
muscle may be explained by the greater 
macroautophagic response of this tissue 
to decreased amino acids. As the authors 
note in their paper, other disorders of 
lysosomal function produce autophagic 
vacuolar myopathies in humans that 
closely resemble XMEA. Prolonged use 
of chloroquine, a drug for treating malaria 
and rheumatoid arthritis, and Danon dis-
ease, an X-linked dominant myopathy 
due to LAMP2 deficiency, cause skeletal 
myopathies that closely resemble XMEA 
(although brain and heart are also clini-
cally affected in Danon disease) (Kalimo 
et al., 1988; Nishino et al., 2000). Chloro-
quine accumulates in lysosomes, where, 
just like V-ATPase deficiency, it elevates 
lysosomal pH and blocks autophagy. By 
contrast, LAMP2 deficiency affects chap-
erone-mediated autophagy, lysosomal 
biogenesis, lysosome-autophagosome 
fusion, and lysosomal movement along 
microtubules. Defects in multiple lyso-
somal functions could easily account for 
the more widespread organ involvement seen in Danon disease. Development of 
an animal model of VMA21 deficiency 
may reveal the reasons for the muscle-
specific phenotype of XMEA.
Overall, the work of Ramachandran 
et al. is praiseworthy, not only for iden-
tifying primary VMA21 deficiency as the 
cause of XMEA, but also for the elegant 
characterization of the mechanism result-
ing in pathogenic autophagic vacuoles. 
The findings confirm the importance of 
V-ATPase in the regulation of lysosomal 
pH, which appears to impact autophagy 
directly by impairing lysosomal degrada-
tion and indirectly through modulation of 
the mTOR pathway in skeletal muscle. 
As the authors suggest, elucidation of 
V-ATPase functions and the conse-
quences of dysfunction may be useful 
in the design of V-ATPase modulators to 
treat not only XMEA but also malaria, HIV, 
osteoporosis, and cancer metastasis.
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